TY - JOUR
T1 - Meta-analysis
T2 - The outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
AU - Andriulli, A.
AU - Mangia, A.
AU - Iacobellis, A.
AU - Ippolito, A.
AU - Leandro, G.
AU - Zeuzem, S.
PY - 2008/8
Y1 - 2008/8
N2 - Background: Anti-viral therapy seems more successful in HCV genotype 2 than genotype 3-infected patients. Aim: To report sustained virological response (SVR) rates for HCV-2 and HCV-3 infection. Methods: Meta-analyses were carried out on SVR data on 2275 patients treated for 24 weeks in eight individual trials and on 968 patients with rapid virological response (RVR) treated for 12-16 weeks or 24 weeks in four studies. Results: After 24 weeks of therapy, SVR rates were 74% and 68%, respectively, for HCV-2 and HCV-3 genotype patients. Among high viraemics, SVR rate in HCV-2 infection (75%) differed from the 58% value in HCV-3 infection. Among low viraemic patients, respective rates were 79% and 75%. In RVR patients treated for 12-16 or 24 weeks, SVR rates in HCV-2 infection were 83% and 84%, respectively, and in HCV-3 infection 84% and 86%. In patients without RVR treated for 24 weeks, SVR was higher in HCV-2, with a 17.8% weighted difference. Conclusions: Twenty-four weeks of therapy should remain standard duration for HCV-2 and low viraemic HCV-3 patients. In RVR patients, HCV-3 patients respond to short-treatment as well as HCV-2 patients, irrespective of basal viraemia. Patients without RVR may need longer treatment than the recommended 24 weeks.
AB - Background: Anti-viral therapy seems more successful in HCV genotype 2 than genotype 3-infected patients. Aim: To report sustained virological response (SVR) rates for HCV-2 and HCV-3 infection. Methods: Meta-analyses were carried out on SVR data on 2275 patients treated for 24 weeks in eight individual trials and on 968 patients with rapid virological response (RVR) treated for 12-16 weeks or 24 weeks in four studies. Results: After 24 weeks of therapy, SVR rates were 74% and 68%, respectively, for HCV-2 and HCV-3 genotype patients. Among high viraemics, SVR rate in HCV-2 infection (75%) differed from the 58% value in HCV-3 infection. Among low viraemic patients, respective rates were 79% and 75%. In RVR patients treated for 12-16 or 24 weeks, SVR rates in HCV-2 infection were 83% and 84%, respectively, and in HCV-3 infection 84% and 86%. In patients without RVR treated for 24 weeks, SVR was higher in HCV-2, with a 17.8% weighted difference. Conclusions: Twenty-four weeks of therapy should remain standard duration for HCV-2 and low viraemic HCV-3 patients. In RVR patients, HCV-3 patients respond to short-treatment as well as HCV-2 patients, irrespective of basal viraemia. Patients without RVR may need longer treatment than the recommended 24 weeks.
UR - http://www.scopus.com/inward/record.url?scp=47749115740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47749115740&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2008.03763.x
DO - 10.1111/j.1365-2036.2008.03763.x
M3 - Article
C2 - 18549461
AN - SCOPUS:47749115740
VL - 28
SP - 397
EP - 404
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 4
ER -